Lantern Pharma Statistics

Total Valuation

Lantern Pharma has a market cap or net worth of $33.43 million. The enterprise value is $15.96 million.

Market Cap	33.43M
Enterprise Value	15.96M

Important Dates

The last earnings date was Thursday, May 15, 2025, before market open.

Earnings Date	May 15, 2025
Ex-Dividend Date	n/a

Share Statistics

Lantern Pharma has 10.78 million shares outstanding. The number of shares has decreased by -0.38% in one year.

Current Share Class	10.78M
Shares Outstanding	10.78M
Shares Change (YoY)	-0.38%
Shares Change (QoQ)	-0.88%
Owned by Insiders (%)	0.42%
Owned by Institutions (%)	11.57%
Float	8.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.11
P/TBV Ratio	2.11
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.86, with a Debt / Equity ratio of 0.01.

Current Ratio	4.86
Quick Ratio	4.60
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -75.66% and return on invested capital (ROIC) is -50.20%.

Return on Equity (ROE)	-75.66%
Return on Assets (ROA)	-43.68%
Return on Invested Capital (ROIC)	-50.20%
Return on Capital Employed (ROCE)	-126.46%
Revenue Per Employee	n/a
Profits Per Employee	-$828,216
Employee Count	24
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -49.46% in the last 52 weeks. The beta is 1.62, so Lantern Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.62
52-Week Price Change	-49.46%
50-Day Moving Average	3.56
200-Day Moving Average	3.76
Relative Strength Index (RSI)	42.43
Average Volume (20 Days)	58,213

Short Selling Information

The latest short interest is 254,171, so 2.36% of the outstanding shares have been sold short.

Short Interest	254,171
Short Previous Month	273,109
Short % of Shares Out	2.36%
Short % of Float	3.17%
Short Ratio (days to cover)	6.34

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-21.26M
Pretax Income	-17.75M
Net Income	-19.88M
EBITDA	-21.24M
EBIT	-21.26M
Earnings Per Share (EPS)	-$1.85

Full Income Statement

Balance Sheet

The company has $19.72 million in cash and $194,931 in debt, giving a net cash position of $19.53 million or $1.81 per share.

Cash & Cash Equivalents	19.72M
Total Debt	194,931
Net Cash	19.53M
Net Cash Per Share	$1.81
Equity (Book Value)	16.78M
Book Value Per Share	1.56
Working Capital	16.54M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$19.12 million and capital expenditures -$11,537, giving a free cash flow of -$19.13 million.

Operating Cash Flow	-19.12M
Capital Expenditures	-11,537
Free Cash Flow	-19.13M
FCF Per Share	-$1.77

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Lantern Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.38%
Shareholder Yield	0.38%
Earnings Yield	-56.02%
FCF Yield	-53.92%

Analyst Forecast

The average price target for Lantern Pharma is $25.00, which is 706.45% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$25.00
Price Target Difference	706.45%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-14.01%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1